WO2018094136A1 - T-butyl 2-carbamothioyl-2-(3-(5-(4-cyanophenoxy)pyridin-2-yl)-2-(2,4- difluorophenyl)-3,3-difluoro-2-hydroxypropyl)hydrazine-l- carboxylate and processes of preparation - Google Patents

T-butyl 2-carbamothioyl-2-(3-(5-(4-cyanophenoxy)pyridin-2-yl)-2-(2,4- difluorophenyl)-3,3-difluoro-2-hydroxypropyl)hydrazine-l- carboxylate and processes of preparation Download PDF

Info

Publication number
WO2018094136A1
WO2018094136A1 PCT/US2017/062147 US2017062147W WO2018094136A1 WO 2018094136 A1 WO2018094136 A1 WO 2018094136A1 US 2017062147 W US2017062147 W US 2017062147W WO 2018094136 A1 WO2018094136 A1 WO 2018094136A1
Authority
WO
WIPO (PCT)
Prior art keywords
isothiocyanate
compound
hydrazine
butyl
difluorophenyl
Prior art date
Application number
PCT/US2017/062147
Other languages
French (fr)
Inventor
Kaitlyn Gray
Qiang Yang
Nicholas R. BABIJ
Yan Hao
Jim RENGA
Original Assignee
Vps-3, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vps-3, Inc. filed Critical Vps-3, Inc.
Priority to US16/462,201 priority Critical patent/US20190276403A1/en
Priority to EP17872175.9A priority patent/EP3555047A4/en
Priority to CN201780070404.XA priority patent/CN109963837A/en
Priority to BR112019009760A priority patent/BR112019009760A2/en
Publication of WO2018094136A1 publication Critical patent/WO2018094136A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5

Definitions

  • metalloenzyme inhibitor compounds and their use as fungicides.
  • the disclosure of this application is expressly incorporated by reference herein.
  • This patent application describes various routes to generate metalloenzyme inhibiting fungicides. It may be advantageous to provide more direct and efficient methods for the preparation of metalloenzyme inhibiting fungicides and related compounds, e.g., by the use of reagents and/or chemical intermediates which provide improved time and cost efficiency.
  • the compound of Formula II may be prepared by contacting a compound of Formula III with i-butyl carbazate.
  • R benzoyl or Me 3 Si.
  • halogen refers to one or more halogen atoms, defined as F, CI, Br, and I.
  • organometallic refers to an organic compound containing a metal, especially a compound in which a metal atom is bonded directly to a carbon atom.
  • Room temperature is defined herein as about 20 °C to about 25 °C.
  • references to the compounds of Formulas I- III are read as also including optical isomers and salts. Specifically, when compounds of Formulas I- III contain a chiral carbon, it is understood that such compounds include optical isomers and racemates thereof.
  • Exemplary salts may include: hydrochloride salts, hydrobromide salts, hydroiodide salts, and the like.
  • the benzoyl intermediate la was identified by LCMS (ESIMS m/z 696.1 [(M+H) + ]). After an additional 30 min, anhydrous hydrazine (1.47 mL, 46.9 mmol) was added. The mixture was stirred at 0 °C for 1 h then room temperature for 30 min. The reaction was diluted with ethyl acetate and washed with sat. ammonium chloride. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated to a pale yellow oil. Methanol (25 mL) was added to the oil and after a few minutes of stirring a white precipitate had formed.
  • Method B To a solution of i-butyl 2-(3-(5-(4-cyanophenoxy)pyridin-2-yl)-2-(2,4- difluorophenyl)-3,3-difluoro-2-hydroxypropyl)hydrazine-l-carboxylate (II, 1 g, 1.596 mmol) in ethyl acetate (9.4 mL) was added isothiocyanatotrimethylsilane (0.540 mL, 3.83 mmol) and the reaction was stirred at 80 °C for 18 h. NMR indicated incomplete conversion so additional isothiocyanatotrimethylsilane (0.540 mL, 3.83 mmol) was added and the reaction stirred at 80 °C for 6 h. NMR indication the reaction was still incomplete so more
  • isothiocyanatotrimethylsilane (0.540 mL, 3.83 mmol) was added and the reaction stirred at 80 °C for 17 h. The reaction was allowed to cool to room temperature and 1 N HCl (10 mL) was added. The phases were separated and the organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated to a yellow foam. The yellow foam was dissolved in methylene chloride and purified by silica gel column chromatography eluting with 0-60% ethyl acetate/hexanes.
  • Organic isothiocyanates for use in this process step may include acyl isothiocyanates such as, for example, benzoyl isothiocyanate (to make the compound of Formula la), and silyl isothiocyanates such as, for example, trimethylsilyl isothiocyanate (to make the compound of Formula lb).
  • acyl isothiocyanates such as, for example, benzoyl isothiocyanate (to make the compound of Formula la)
  • silyl isothiocyanates such as, for example, trimethylsilyl isothiocyanate (to make the compound of Formula lb).
  • Cleaving reagents used to remove the R-group from the compound of Formula la to prepare the compound of Formula I may be selected from the group including hydrazine, ammonia, sodium methoxide, and methylamine.
  • Cleaving reagents used to remove the R- group from the compound of Formula lb to prepare the compound of Formula I may be selected from: a) fluoride compounds such as, for example, a tetraalkylammonium fluoride and potassium fluoride, and b) an acid such as, for example, hydrochloric acid (HCl), hydrobromic acid (HBr), or sulfuric acid (H 2 S0 4 ).
  • the contacting of the compound of Formula II with the organic isothiocyanate may be carried out between about -20 °C and about 100 °C, and the contacting with the cleaving reagent may be carried out between about -20 °C and about 100 °C.
  • Solvents for use in this process step may include one or more than one of THF (tetrahydrofuran), EtOAc, 2-Me-THF, dioxane, MeCN (acetonitrile), and DME (1,2- dimethoxyethane) .
  • i-Butyl 2-(3-(5-(4-cyanophenoxy)pyridin-2-yl)-2-(2,4-difluorophenyl)-3,3-difluoro-2- hydroxypropyl)hydrazine-l-carboxylate (II) may be prepared from 4-((6-((2-(2,4- difluorophenyl)oxiran-2-yl)difluoromethyl)pyridin-3-yl)oxy)benzonitrile (III) as shown in Example 2.
  • the contacting of the compound of Formula III with i-butyl carbazate may be carried out from about 25 °C to about 100 °C or from about 60 °C to about 90 °C.
  • Solvents for use in this process step may include alcohols such as methanol, ethanol, and isopropanol, as well as aprotic solvents such as THF (tetrahydrofuran), acetonitrile, DMSO (dimethylsulfoxide), DMF (N,N-dimethylformamide), and mixtures of any of these solvents.
  • alcohols such as methanol, ethanol, and isopropanol
  • aprotic solvents such as THF (tetrahydrofuran), acetonitrile, DMSO (dimethylsulfoxide), DMF (N,N-dimethylformamide), and mixtures of any of these solvents.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided herein is a process for the preparation of i-butyl 2-carbamothioyl-2-(3-(5-(4- cyanophenoxy)pyridin-2-yl)-2-(2,4-difluorophenyl)-3,3-difluoro-2-hydroxypropyl)hydrazine- 1-carboxylate.

Description

ί-BUTYL 2-CARBAMOTHIOYL-2-(3-(5-(4-CYANOPHENOXY)PYRIDIN-2-YL)-2-(2,4- DIFLUOROPHENYL)-3,3-DIFLUORO-2-HYDROXYPROPYL)HYDRAZINE-l- CARBOXYLATE AND PROCESSES OF PREPARATION
CROSS-REFERENCE TO RELATED APPLICATIONS
The present application claims priority under 35 U.S.C. § 119(e) to U.S. provisional patent application, U.S.S.N. 62/423,858, filed November 18, 2016, the entire contents of which is incorporated herein by reference.
FIELD
Provided herein is i-butyl 2-carbamothioyl-2-(3-(5-(4-cyanophenoxy)pyridin-2-yl)-2- (2,4-difluorophenyl)-3,3-difluoro-2-hydroxypropyl)hydrazine- l-carboxylate and processes of preparation.
BACKGROUND
U.S. Patent Application Serial No. 62/163,106 describes inter alia certain
metalloenzyme inhibitor compounds and their use as fungicides. The disclosure of this application is expressly incorporated by reference herein. This patent application describes various routes to generate metalloenzyme inhibiting fungicides. It may be advantageous to provide more direct and efficient methods for the preparation of metalloenzyme inhibiting fungicides and related compounds, e.g., by the use of reagents and/or chemical intermediates which provide improved time and cost efficiency.
SUMMARY OF THE DISCLOSURE
Provided herein is the compound i-butyl 2-carbamothioyl-2-(3-(5-(4- cyanophenoxy)pyridin-2-yl)-2-(2,4-difluorophenyl)-3,3-difluoro-2-hydroxypropyl)hydrazine- 1-carboxylate (I), which is useful for preparing certain metalloenzyme inhibitor compounds, and processes for its preparation. In one embodiment, provided herein, is a process for the preparation of the compound of the Formula I:
Figure imgf000003_0001
I which comprises contacting a compound of Formula II with an organic isothiocyanate and then with a cleaving reagent.
Figure imgf000003_0002
In another embodiment, the compound of Formula II may be prepared by contacting a compound of Formula III with i-butyl carbazate.
Figure imgf000003_0003
III
Another aspect of the present disclosure are the novel intermediates produced in the present process, viz., the compounds consisting of: a)
Figure imgf000004_0001
b)
Figure imgf000004_0002
and, c)
Figure imgf000004_0003
wherein R = benzoyl or Me3Si.
The term "halogen" or "halo" refers to one or more halogen atoms, defined as F, CI, Br, and I. The term "organometallic" refers to an organic compound containing a metal, especially a compound in which a metal atom is bonded directly to a carbon atom.
Room temperature (RT) is defined herein as about 20 °C to about 25 °C. Throughout the disclosure, references to the compounds of Formulas I- III (including la and lb) are read as also including optical isomers and salts. Specifically, when compounds of Formulas I- III contain a chiral carbon, it is understood that such compounds include optical isomers and racemates thereof. Exemplary salts may include: hydrochloride salts, hydrobromide salts, hydroiodide salts, and the like.
Certain compounds disclosed in this document can exist as one or more isomers. It will be appreciated by those skilled in the art that one isomer may be more active than the others. The structures disclosed in the present disclosure are drawn in only one geometric form for clarity, but are intended to represent all geometric and tautomeric forms of the molecule.
The embodiments described above are intended merely to be exemplary, and those skilled in the art will recognize, or will be able to ascertain using no more than routine experimentation, numerous equivalents of specific processes, materials and procedures. All such equivalents are considered to be within the scope of the invention and are encompassed by the appended claims.
DETAILED DESCRIPTION i-Butyl 2-carbamothioyl-2-(3-(5-(4-cyanophenoxy)pyridin-2-yl)-2-(2,4- difluorophenyl)-3,3-difluoro-2-hydroxypropyl)hydrazine-l-carboxylate (I) may be prepared from i-butyl 2-(3-(5-(4-cyanophenoxy)pyridin-2-yl)-2-(2,4-difluorophenyl)-3,3-difluoro-2- hydroxypropyl)hydrazine-l-carboxylate (II) as shown in Example 1.
Example 1: Preparation of i-butyl 2-carbamothioyl-2-(3-(5-(4-cyanophenoxy)pyridin-2-yl)- 2-(2,4-difluorophenyl)-3,3-difluoro-2-hydroxypropyl)hydrazine-l-carboxylate (I)
Figure imgf000006_0001
Figure imgf000006_0002
Method A: To i-butyl 2-(3-(5-(4-cyanophenoxy)pyridin-2-yl)-2-(2,4-difluorophenyl)- 3,3-difluoro-2-hydroxypropyl)hydrazine- l-carboxylate (II) (5 g, 9.39 mmol) in THF (31.3 mL) at 0 °C was added benzoyl isothiocyanate (1.199 mL, 8.92 mmol). After 30 min additional benzoyl isothiocyanate (0.1 mL, 0.74 mmol) was added. The benzoyl intermediate la was identified by LCMS (ESIMS m/z 696.1 [(M+H)+]). After an additional 30 min, anhydrous hydrazine (1.47 mL, 46.9 mmol) was added. The mixture was stirred at 0 °C for 1 h then room temperature for 30 min. The reaction was diluted with ethyl acetate and washed with sat. ammonium chloride. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated to a pale yellow oil. Methanol (25 mL) was added to the oil and after a few minutes of stirring a white precipitate had formed. The slurry was filtered and the solid rinsed with methanol giving i-butyl 2-carbamothioyl-2-(3-(5-(4-cyanophenoxy)pyridin- 2-yl)-2-(2,4-difluorophenyl)-3,3-difluoro-2-hydroxypropyl)hydrazine-l-carboxylate (I) (4.29 g, 7.25 mmol, 77% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 8.76 (s, 1H),
8.45 (d, J = 11.9 Hz, 2H), 7.96 - 7.86 (m, 2H), 7.70 (dd, J = 8.6, 2.8 Hz, 2H), 7.58 (d, J = 8.4 Hz, 1H), 7.53 7.40 (m, 1H), 7.22 - 7.15 (m, 2H), 7.12 (t, = 11.0 Hz, 1H), 7.01 (d, = 8.8 Hz, 1H), 6.37 (s, 1H), 5.45 (d, = 15.7 Hz, 1H), 4.47 (d, = 15.3 Hz, 1H), 1.40 (s, 9H). 19F NMR (376 MHz, DMSO-d6) δ -104.72 (d, J = 122.8 Hz), -107.49 - -109.12 (m), -111.08 - -111.85 (m). ESIMS m/z 592.2 [(M+H)+].
Method B: To a solution of i-butyl 2-(3-(5-(4-cyanophenoxy)pyridin-2-yl)-2-(2,4- difluorophenyl)-3,3-difluoro-2-hydroxypropyl)hydrazine-l-carboxylate (II, 1 g, 1.596 mmol) in ethyl acetate (9.4 mL) was added isothiocyanatotrimethylsilane (0.540 mL, 3.83 mmol) and the reaction was stirred at 80 °C for 18 h. NMR indicated incomplete conversion so additional isothiocyanatotrimethylsilane (0.540 mL, 3.83 mmol) was added and the reaction stirred at 80 °C for 6 h. NMR indication the reaction was still incomplete so more
isothiocyanatotrimethylsilane (0.540 mL, 3.83 mmol) was added and the reaction stirred at 80 °C for 17 h. The reaction was allowed to cool to room temperature and 1 N HCl (10 mL) was added. The phases were separated and the organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated to a yellow foam. The yellow foam was dissolved in methylene chloride and purified by silica gel column chromatography eluting with 0-60% ethyl acetate/hexanes. Product containing fractions were collected and concentrated giving t- butyl 2-carbamothioyl-2-(3-(5-(4-cyanophenoxy)pyridin-2-yl)-2-(2,4-difluorophenyl)-3,3- difluoro-2-hydroxypropyl)hydrazine-l-carboxylate (I) as a yellow foam (460 mg, 0.778 mmol, 49% yield). Analytical data was consistent with that of previously obtained samples.
Organic isothiocyanates for use in this process step may include acyl isothiocyanates such as, for example, benzoyl isothiocyanate (to make the compound of Formula la), and silyl isothiocyanates such as, for example, trimethylsilyl isothiocyanate (to make the compound of Formula lb).
Cleaving reagents used to remove the R-group from the compound of Formula la to prepare the compound of Formula I, may be selected from the group including hydrazine, ammonia, sodium methoxide, and methylamine. Cleaving reagents used to remove the R- group from the compound of Formula lb to prepare the compound of Formula I, may be selected from: a) fluoride compounds such as, for example, a tetraalkylammonium fluoride and potassium fluoride, and b) an acid such as, for example, hydrochloric acid (HCl), hydrobromic acid (HBr), or sulfuric acid (H2S04). The contacting of the compound of Formula II with the organic isothiocyanate may be carried out between about -20 °C and about 100 °C, and the contacting with the cleaving reagent may be carried out between about -20 °C and about 100 °C.
Solvents for use in this process step may include one or more than one of THF (tetrahydrofuran), EtOAc, 2-Me-THF, dioxane, MeCN (acetonitrile), and DME (1,2- dimethoxyethane) . i-Butyl 2-(3-(5-(4-cyanophenoxy)pyridin-2-yl)-2-(2,4-difluorophenyl)-3,3-difluoro-2- hydroxypropyl)hydrazine-l-carboxylate (II) may be prepared from 4-((6-((2-(2,4- difluorophenyl)oxiran-2-yl)difluoromethyl)pyridin-3-yl)oxy)benzonitrile (III) as shown in Example 2.
Example 2: Preparation of i-butyl 2-(3-(5-(4-cyanophenoxy)pyridin-2-yl)-2-(2,4- difluorophenyl)-3,3-difluoro-2-hydroxypropyl)hydrazine-l-carboxylate (II)
Figure imgf000008_0001
III
To a slurry of 4-((6-((2-(2,4-difluorophenyl)oxiran-2-yl)difluoromethyl)pyridin-3- yl)oxy)benzonitrile (III) (5 g, 12.49 mmol) in ethanol (40 mL) was added i-butyl carbazate (4.13 g, 31.2 mmol) and the reaction was heated at 80 °C for 24 h, at which point the starting epoxide (III) was completely consumed. The reaction was allowed to cool to 45 °C and seeded with crystals of product II causing the reaction to cloud. Additional ethanol (40 mL) was added, and the reaction was cooled to room temperature overnight. The resulting slurry was cooled with an ice bath for 30 min and filtered. The solids were rinsed with ethanol (30 mL) and dried under vacuum providing i-butyl 2-(3-(5-(4-cyanophenoxy)pyridin-2-yl)-2- (2,4-difluorophenyl)-3,3-difluoro-2-hydroxypropyl)hydrazine-l-carboxylate (II) as a white solid (5.42 g, 9.67 mmol, 77% yield). 1H NMR (400 MHz, CDC13) δ 8.37 (d, J = 2.7 Hz, 1H), 7.72 - 7.64 (m, 2H), 7.55 (td, = 8.8, 6.6 Hz, 1H), 7.48 (d, = 8.6 Hz, 1H), 7.37 (dd, = 8.7, 2.7 Hz, 1H), 7.10 - 7.02 (m, 2H), 6.77 (dddd, = 20.9, 11.4, 8.6, 2.6 Hz, 2H), 3.83 (d, = 13.7 Hz, 1H), 3.74 (dd, 7 = 13.4, 2.8 Hz, 1H), 1.41 (s, 9H). 19F NMR (376 MHz, CDC13) δ -105.15, -108.68 (d, J = 22.1 Hz), -109.24, -110.29. ESIMS m/z 533.1 [(M+H)+].
The contacting of the compound of Formula III with i-butyl carbazate may be carried out from about 25 °C to about 100 °C or from about 60 °C to about 90 °C.
Solvents for use in this process step may include alcohols such as methanol, ethanol, and isopropanol, as well as aprotic solvents such as THF (tetrahydrofuran), acetonitrile, DMSO (dimethylsulfoxide), DMF (N,N-dimethylformamide), and mixtures of any of these solvents.

Claims

WHAT IS CLAIMED IS:
1. A method of making a compound of Formula I comprising:
Figure imgf000010_0001
contacting a compound of Formula II
Figure imgf000010_0002
with an organic isothiocyanate, and a cleaving reagent.
2. The method of Claim 1 wherein the organic isothiocyanate is an acyl isothiocyanate or a silyl isothiocyanate.
3. The method of Claim 2 wherein the acyl isothiocyanate is benzoyl isothiocyanate.
4. The method of Claim 2 wherein the silyl isothiocyanate is trimethylsilyl
isothiocyanate.
5. The method of Claim 1 wherein the cleaving reagent is selected from the group including hydrazine, ammonia, sodium methoxide, methylamine, a fluoride compound and an acid.
6. The method of Claim 1 wherein the contacting with the organic isothiocyanate is carried out between about -20 °C and about 100 °C.
7. The method of Claim 1 wherein the contacting with the cleaving reagent is carried out between about -20 °C and about 100 °C.
8. The method of Claim 1 further comprising the step of contacting the compound of Formula III
Figure imgf000011_0001
III with i-butyl carbazate to prepare the compound of Formula II.
9. The method of Claim 8 further comprising a solvent selected from the group including methanol, ethanol, isopropanol, THF, acetonitrile, DMSO, DMF, and mixtures thereof.
10. The method of Claim 8 wherein the contacting with the i-butyl carbazate is carried out between about 25 °C and about 100 °C.
11. A compound selected from the group consisting of: a)
Figure imgf000011_0002
Figure imgf000012_0001
Figure imgf000012_0002
-11-
PCT/US2017/062147 2016-11-18 2017-11-17 T-butyl 2-carbamothioyl-2-(3-(5-(4-cyanophenoxy)pyridin-2-yl)-2-(2,4- difluorophenyl)-3,3-difluoro-2-hydroxypropyl)hydrazine-l- carboxylate and processes of preparation WO2018094136A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US16/462,201 US20190276403A1 (en) 2016-11-18 2017-11-17 T-butyl 2-carbamothioyl-2-(3-(5-(4-cyanophenoxy)pyridin-2-yl)-2-(2,4-difluorophenyl)-3,3-difluoro-2-hydroxypropyl)hydrazine-1-carboxylate and processes of preparation
EP17872175.9A EP3555047A4 (en) 2016-11-18 2017-11-17 T-butyl 2-carbamothioyl-2-(3-(5-(4-cyanophenoxy)pyridin-2-yl)-2-(2,4- difluorophenyl)-3,3-difluoro-2-hydroxypropyl)hydrazine-1-carboxylate and processes of preparation
CN201780070404.XA CN109963837A (en) 2016-11-18 2017-11-17 2- aminothio formoxyl -2- (the fluoro- 2- hydroxypropyl of 3- (5- (4- cyano-benzene oxygen) pyridine -2- base) -2- (2,4 difluorobenzene base) -3,3- two) hydrazine-l- t-butyl formate and preparation method
BR112019009760A BR112019009760A2 (en) 2016-11-18 2017-11-17 t-Butyl 2-carbamothioyl-2- (3- (5- (4-cyanophenoxy) pyridin-2-yl) -2- (2,4-difluorophenyl) -3,3-difluoro-2-hydroxypropyl) hydrazine-1 - carboxylate and preparation processes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662423858P 2016-11-18 2016-11-18
US62/423,858 2016-11-18

Publications (1)

Publication Number Publication Date
WO2018094136A1 true WO2018094136A1 (en) 2018-05-24

Family

ID=62145694

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/062147 WO2018094136A1 (en) 2016-11-18 2017-11-17 T-butyl 2-carbamothioyl-2-(3-(5-(4-cyanophenoxy)pyridin-2-yl)-2-(2,4- difluorophenyl)-3,3-difluoro-2-hydroxypropyl)hydrazine-l- carboxylate and processes of preparation

Country Status (5)

Country Link
US (1) US20190276403A1 (en)
EP (1) EP3555047A4 (en)
CN (1) CN109963837A (en)
BR (1) BR112019009760A2 (en)
WO (1) WO2018094136A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020020813A1 (en) 2018-07-25 2020-01-30 Bayer Aktiengesellschaft Fungicidal active compound combinations

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092087A1 (en) * 2001-05-11 2002-11-21 Vertex Pharmaceuticals Incorporated 2,5-disubstituted pyridine, pyrimidine, pyridazine and 1, 2, 4-triazine derivatives for use as p38 inhibitors
WO2004018485A1 (en) * 2002-08-26 2004-03-04 Ranbaxy Laboratories Limited Azole derivatives as antifungal agents
WO2005066164A1 (en) * 2003-12-22 2005-07-21 Eli Lilly And Company Opioid receptor antagonists
WO2005092836A1 (en) * 2004-03-15 2005-10-06 Eli Lilly And Company Opioid receptor antagonists
WO2015143188A1 (en) * 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and proceses for their preparation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11051514B2 (en) * 2015-05-18 2021-07-06 Mycovia Pharmaceuticals, Inc. Antifungal compounds
EP3541796A4 (en) * 2016-11-18 2020-03-25 Dow AgroSciences LLC 4-((6-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(5-mercapto-1h
EP3541799A4 (en) * 2016-11-18 2020-04-01 Dow Agrosciences Llc 4-((6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(5-mercapto-1h-1,2,4-triazol-1-yl)propyl)pyridin-3-yl)oxy)benzonitrile and processes of preparation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092087A1 (en) * 2001-05-11 2002-11-21 Vertex Pharmaceuticals Incorporated 2,5-disubstituted pyridine, pyrimidine, pyridazine and 1, 2, 4-triazine derivatives for use as p38 inhibitors
WO2004018485A1 (en) * 2002-08-26 2004-03-04 Ranbaxy Laboratories Limited Azole derivatives as antifungal agents
WO2005066164A1 (en) * 2003-12-22 2005-07-21 Eli Lilly And Company Opioid receptor antagonists
WO2005092836A1 (en) * 2004-03-15 2005-10-06 Eli Lilly And Company Opioid receptor antagonists
WO2015143188A1 (en) * 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and proceses for their preparation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SATTIGERI, J. A. ET AL.: "Synthesis of 2[(1R,2R)-2-(2,4-difluorophenyl)-2- hydroxy-1-methyl-3-(1H-1,2,4-triazol-yl)propyl]-4-[4-tetrafluoropropoxy) phenyl]-3-(2H,4H)-1,2,4-triazol-3-thione, a novel and potent azole antifungal agent", SYNTHETIC COMMUNICATIONS, vol. 40, no. 6, 2010, pages 833 - 838, XP055504413 *
See also references of EP3555047A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020020813A1 (en) 2018-07-25 2020-01-30 Bayer Aktiengesellschaft Fungicidal active compound combinations

Also Published As

Publication number Publication date
CN109963837A (en) 2019-07-02
EP3555047A1 (en) 2019-10-23
US20190276403A1 (en) 2019-09-12
EP3555047A4 (en) 2020-04-29
BR112019009760A2 (en) 2019-08-13

Similar Documents

Publication Publication Date Title
US10513506B2 (en) 4-((6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)pyridin-3-yl and processes of preparation
US20190382369A1 (en) 4-((6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1h-1,2,4-triazol-1-yl)propyl)pyridin-3-yl)oxy)benzonitrile and processes of preparation
CA3005743A1 (en) 4-((6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1h-1,2,4-triazol-1-yl)propyl)pyridin-3-yl)oxy)benzonitrile and processes of preparation
EP3541794B1 (en) 4-((6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(5-mercapto-1h-1,2,4-triazol-1-yl)propyl)pyridin-3-yl)oxy)benzonitrile and processes of preparation
US20180327359A1 (en) 4-((6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-oxoethyl)pyridin-3-yl)oxy)benzonitrile and processes of preparation
WO2018094133A1 (en) 4-((6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(5-mercapto-1h-1,2,4-triazol-1-yl)propyl)pyridin-3-yl)oxy)benzonitrile and processes of preparation
WO2018094147A1 (en) 4-((6-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(5-mercapto-1h-1,2,4-triazol-1-yl)propyl)pyridin-3-yl)oxy)benzonitrile and processes of preparation
WO2018094136A1 (en) T-butyl 2-carbamothioyl-2-(3-(5-(4-cyanophenoxy)pyridin-2-yl)-2-(2,4- difluorophenyl)-3,3-difluoro-2-hydroxypropyl)hydrazine-l- carboxylate and processes of preparation
US10787431B2 (en) 4-((6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(5-mercapto-1h-1,2,4-triazol-1-yl)propyl)pyridin-3-yl)oxy)benzonitrile and processes of preparation
EP3541800A1 (en) 4-((6-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(5-mercapto-1h-1,2,4-triazol-1-yl)propyl)pyridin-3-yl)oxy)benzonitrile and processes of preparation
US20190284161A1 (en) 4-((6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(5-mercapto-1h-1,2,4-triazol-1-yl)propyl)pyridin-3-yl)oxy)benzonitrile and processes of preparation
US20190330184A1 (en) 4-((6-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3(5-mercapto-1h-1,2,4-triazol-1-yl)propyl)pyridin-3-yl)oxy)benzonitrile and processes of preparation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17872175

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112019009760

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2017872175

Country of ref document: EP

Effective date: 20190618

ENP Entry into the national phase

Ref document number: 112019009760

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20190514